Similar articles

• [New therapeutic concepts in cerebrovascular insufficiency].

  Wender M. Wender M. Neurol Neurochir Pol. 1986 Sep-Oct;20(5):401-3. Neurol Neurochir Pol. 1986. PMID: 3587509 Polish. No abstract available.
• Pharmacological studies on a new Dihydrothienopyridine calcium antagonist. 2nd communication: effects of S-(+)-methyl-4,7-dihydro-3-isobutyl-6-methyl-4- (3-nitrophenyl)thieno[2,3-b]pyridine-5-carboxylate on the 1,4-dihydropyridine binding sites in the brain and on isolated arteries in the Cynomolgus monkey.

  Nakajima M, Adachi I, Ueda M. Nakajima M, et al. Arzneimittelforschung. 1993 Dec;43(12):1276-82. Arzneimittelforschung. 1993. PMID: 8141814
• [Ion channels of vascular smooth muscle and pharmacological effects of calcium antagonists and potassium channel openers].

  Kitamura K, Ogata R. Kitamura K, et al. Fukuoka Igaku Zasshi. 1994 Nov;85(11):309-13. Fukuoka Igaku Zasshi. 1994. PMID: 7851831 Japanese. No abstract available.
• Vascular effects of calcium antagonists. Uses in some cerebrovascular disorders.

  Marin J. Marin J. Gen Pharmacol. 1988;19(3):295-306. doi: 10.1016/0306-3623(88)90020-1. Gen Pharmacol. 1988. PMID: 2458295 Review.
• [Advance in calcium channel blockers relaxing corpus cavernosum smooth muscle].

  Xiao HJ, Liu JH. Xiao HJ, et al. Zhonghua Nan Ke Xue. 2003 Feb;9(1):55-7. Zhonghua Nan Ke Xue. 2003. PMID: 12680335 Review. Chinese.